van der Hoek, S.; Koomen, J.V.; van Bommel, E.J.M.; Mosterd, C.M.; Scholtes, R.A.; Hesp, A.C.; Stevens, J.; van Raalte, D.H.; Heerspink, H.J.L.
Exposure–Response Analysis of the Sodium–Glucose Cotransporter-2 Inhibitors Dapagliflozin and Empagliflozin on Kidney Hemodynamics in Patients with Type 2 Diabetes. J. Pers. Med. 2023, 13, 747.
https://doi.org/10.3390/jpm13050747
AMA Style
van der Hoek S, Koomen JV, van Bommel EJM, Mosterd CM, Scholtes RA, Hesp AC, Stevens J, van Raalte DH, Heerspink HJL.
Exposure–Response Analysis of the Sodium–Glucose Cotransporter-2 Inhibitors Dapagliflozin and Empagliflozin on Kidney Hemodynamics in Patients with Type 2 Diabetes. Journal of Personalized Medicine. 2023; 13(5):747.
https://doi.org/10.3390/jpm13050747
Chicago/Turabian Style
van der Hoek, Sjoukje, Jeroen V. Koomen, Erik J. M. van Bommel, Charlotte M. Mosterd, Rosalie A. Scholtes, Anne C. Hesp, Jasper Stevens, Daniel H. van Raalte, and Hiddo J. L. Heerspink.
2023. "Exposure–Response Analysis of the Sodium–Glucose Cotransporter-2 Inhibitors Dapagliflozin and Empagliflozin on Kidney Hemodynamics in Patients with Type 2 Diabetes" Journal of Personalized Medicine 13, no. 5: 747.
https://doi.org/10.3390/jpm13050747
APA Style
van der Hoek, S., Koomen, J. V., van Bommel, E. J. M., Mosterd, C. M., Scholtes, R. A., Hesp, A. C., Stevens, J., van Raalte, D. H., & Heerspink, H. J. L.
(2023). Exposure–Response Analysis of the Sodium–Glucose Cotransporter-2 Inhibitors Dapagliflozin and Empagliflozin on Kidney Hemodynamics in Patients with Type 2 Diabetes. Journal of Personalized Medicine, 13(5), 747.
https://doi.org/10.3390/jpm13050747
